Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PARP1P2 (poly (ADP-ribose) polymerase family, member 1 pseudogene 2) is classified as a **pseudogene**, meaning it is a DNA sequence similar to the functional PARP1 gene but is not transcribed and/or translated into a functional protein[6]. It does not encode a protein, does not have known biological function, and is not implicated directly as a molecular target in therapeutic contexts. Pseudogenes like PARP1P2 may have limited scientific interest as potential non-coding RNA elements or as genomic markers, but they are not therapeutic targets, nor do they participate in protein-centric molecular pathways relevant to disease or drug action. **Important distinction:** The **PARP1 protein** (poly(ADP-ribose) polymerase 1, or PARP1), by contrast, is a therapeutic target in oncology and other fields[1], but PARP1P2 specifically refers to a nonfunctional pseudogene, not to the active enzyme.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Poly(ADP-ribose) polymerase family, member 1 pseudogene 2 (PARP1P2).